Achieving cross-reactivity with pan-ebolavirus antibodies
Achieving cross-reactivity with pan-ebolavirus antibodies
复制标题
DOI：
10.1016/j.coviro.2019.01.003
复制
发表时间：
2019-02-01
影响因子：
5.9
通讯作者：
Saphire, Erica Ollmann
中科院分区：
文献类型：
--
作者：
King, Liam B.;Milligan, Jacob C.;Saphire, Erica Ollmann
丝状病毒是撒哈拉以南非洲地区高致命性疫情的病原体。尽管刚果民主共和国正在部署一种实验性疫苗和多种疗法来对抗正在爆发的埃博拉病毒，但这些疗法仅针对一种丝状病毒物种。目前，人们对开发具有广泛反应性的单克隆抗体（mAb）非常感兴趣，该抗体可用于对抗可能出现的各种埃博拉病毒。到目前为止，这些单克隆抗体的主要靶点是病毒刺突糖蛋白（GP）。在这里，我们概述了具有广泛反应性的 GP 靶向抗体以及可能赋予这种交叉反应性的结构特征。我们还讨论了如何利用这些结构特征来设计引发交叉反应抗体的疫苗抗原。
Filoviruses are the causative agents of highly lethal outbreaks in sub-Saharan Africa. Although an experimental vaccine and several therapeutics are being deployed in the Democratic Republic of Congo to combat the ongoing Ebola virus outbreak, these therapies are specific for only one filovirus species. There is currently significant interest in developing broadly reactive monoclonal antibodies (mAbs) with utility against the variety of ebolaviruses that may emerge. Thus far, the primary target of these mAbs has been the viral spike glycoprotein (GP). Here we present an overview of GP-targeted antibodies that exhibit broad reactivity and the structural characteristics that could confer this cross-reactivity. We also discuss how these structural features could be leveraged to design vaccine antigens that elicit cross-reactive antibodies.